Hilsenbeck SG - Search Results

1

9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice.

Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, Lamph WW, Gottardis MM, Shirley MA, Kuhn JG, Green JE, Brown PH. Wu K, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 2000 Sep;6(9):3696-704. Clin Cancer Res. 2000. PMID: 10999763

2

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.

Burris HA 3rd, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD. Burris HA 3rd, et al. Among authors: hilsenbeck sg. J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20. doi: 10.1093/jnci/84.23.1816. J Natl Cancer Inst. 1992. PMID: 1331485

3

Phase I and pharmacokinetic trial of weekly CPT-11.

Rothenberg ML, Kuhn JG, Burris HA 3rd, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, et al. Rothenberg ML, et al. Among authors: hilsenbeck sg. J Clin Oncol. 1993 Nov;11(11):2194-204. doi: 10.1200/JCO.1993.11.11.2194. J Clin Oncol. 1993. PMID: 8229134 Clinical Trial.

4

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DD. Rothenberg ML, et al. Among authors: hilsenbeck sg. J Clin Oncol. 1996 Apr;14(4):1128-35. doi: 10.1200/JCO.1996.14.4.1128. J Clin Oncol. 1996. PMID: 8648367 Clinical Trial.

5

Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors.

Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Barrington RE, Windle JJ. Hundley JE, et al. Among authors: hilsenbeck sg. Cancer Res. 1997 Feb 15;57(4):600-3. Cancer Res. 1997. PMID: 9044833

6

A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion.

Rodriguez GI, Kuhn JG, Weiss G, De La Cruz P, New P, Fields SM, Eckardt JR, Campbell L, Clark GM, Hilsenbeck SG, Von Hoff DD. Rodriguez GI, et al. Among authors: hilsenbeck sg. Invest New Drugs. 1998;16(1):57-67. doi: 10.1023/a:1006003718255. Invest New Drugs. 1998. PMID: 9740545 Clinical Trial.

7

Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.

Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng Cn, Lee AV, Yee D. Rocha RL, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1997 Jan;3(1):103-9. Clin Cancer Res. 1997. PMID: 9815544

8

Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.

Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Brown RW, et al. Among authors: hilsenbeck sg. Clin Cancer Res. 1996 Mar;2(3):585-92. Clin Cancer Res. 1996. PMID: 9816207

9

Loss of heterozygosity at D14S62 and metastatic potential of breast cancer.

O'Connell P, Fischbach K, Hilsenbeck S, Mohsin SK, Fuqua SA, Clark GM, Osborne CK, Allred DC. O'Connell P, et al. J Natl Cancer Inst. 1999 Aug 18;91(16):1391-7. doi: 10.1093/jnci/91.16.1391. J Natl Cancer Inst. 1999. PMID: 10451444

10

A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions.

Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. Fuqua SA, et al. Cancer Res. 2000 Aug 1;60(15):4026-9. Cancer Res. 2000. PMID: 10945602

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

370 results

Search Page

Filters